Stock Research for EXEL

EXEL

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

EXEL Stock Chart & Research Data

The EXEL chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the EXEL chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


EXEL Due diligence Resources & Stock Charts

The EXEL stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View EXEL Detailed Price Forecast - CNN Money CNN View EXEL Detailed Summary - Google Finance
Yahoo View EXEL Detailed Summary - Yahoo! Finance Zacks View EXEL Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View EXEL Trends & Analysis - Trade-Ideas Barrons View EXEL Major Holders - Barrons
NASDAQ View EXEL Call Transcripts - NASDAQ Seeking View EXEL Breaking News & Analysis - Seeking Alpha
Spotlight View EXEL Annual Report - CompanySpotlight.com OTC Report View EXEL OTC Short Report - OTCShortReport.com
TradeKing View EXEL Fundamentals - TradeKing Charts View EXEL SEC Filings - Bar Chart
WSJ View Historical Prices for EXEL - The WSJ Morningstar View Performance/Total Return for EXEL - Morningstar
MarketWatch View the Analyst Estimates for EXEL - MarketWatch CNBC View the Earnings History for EXEL - CNBC
StockMarketWatch View the EXEL Earnings - StockMarketWatch MacroAxis View EXEL Buy or Sell Recommendations - MacroAxis
Bullish View the EXEL Bullish Patterns - American Bulls Short Pains View EXEL Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View EXEL Stock Mentions - StockTwits PennyStocks View EXEL Stock Mentions - PennyStockTweets
Twitter View EXEL Stock Mentions - Twitter Invest Hub View EXEL Investment Forum News - Investor Hub
Yahoo View EXEL Stock Mentions - Yahoo! Message Board Seeking Alpha View EXEL Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for EXEL - SECform4.com Insider Cow View Insider Transactions for EXEL - Insider Cow
CNBC View EXEL Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for EXEL - OTC Markets
Yahoo View Insider Transactions for EXEL - Yahoo! Finance NASDAQ View Institutional Holdings for EXEL - NASDAQ


Stock Charts

FinViz View EXEL Stock Insight & Charts - FinViz.com StockCharts View EXEL Investment Charts - StockCharts.com
BarChart View EXEL Stock Overview & Charts - BarChart Trading View View EXEL User Generated Charts - Trading View


Latest Financial News for EXEL

Analysts’ Recommendations for Exelixis in April 2018
Posted on Thursday April 19, 2018

In February 2018, Exelixis (EXEL) and its partner Daiichi Sankyo announced that it had submitted a regulatory application for esaxerenone therapy to the Japanese Pharmaceutical and Medical Devices Agency for the treatment of individuals with hypertension. According to the prior agreement between Exelixis and Daiichi Sankyo, Exelixis is set to receive a milestone payment of $20 million from Daiichi Sankyo. Daiichi Sankyo’s regulatory application has been supported by the results of Phase 3 trials evaluating the safety and efficacy of esaxerenone in individuals with essential hypertension compared to eplerenone.


Cabometyx Could Be Exelixis’s Long-Term Growth Driver
Posted on Thursday April 19, 2018

In March 2018, the FDA accepted Exelixis’s (EXEL) supplemental New Drug Application (or sNDA) for Cabometyx as a therapy for the treatment of individuals with advanced hepatocellular carcinoma (or HCC) who have previously undergone therapy. Exelixis’s sNDA was based on the results of its Phase 3 CELESTIAL trial. In October 2017, an independent data-monitoring committee recommended that Exelixis stop its CELESTIAL efficacy trial after a review of the second planned interim analysis, wherein Cabometyx demonstrated statistically significant and clinically meaningful progress in overall survival compared to the placebo in individuals who had already been treated for advanced HCC.


How Exelixis’s Cabomeytx and Cometriq Performed in 4Q17 and 2017
Posted on Wednesday April 18, 2018

In 4Q17, Exelixis’s (EXEL) Cabometyx reported revenue of $90.4 million compared to $44.7 million in 4Q16, which reflected a ~102% rise on a YoY (year-over-year) basis. The FDA’s approval of the drug’s label expansion also boosted its revenue growth in 4Q17. In 2017, Cabometyx generated revenue of $324 million compared to $93.5 million in 2016.


What to Expect from Exelixis in 1Q18
Posted on Wednesday April 18, 2018

In 4Q17, Exelixis (EXEL) generated revenue of $115.9 million compared to $75.7 million in 4Q16, which reflected a ~55% rise on a year-over-year (or YoY) basis and a ~19% fall on a quarter-over-quarter basis. In 4Q17, Exelixis generated revenue of $95.7 million from net product sales and $24.4 million from collaborations. In 4Q17, Cabometyx primarily pushed this revenue growth.


Enter a stock symbol to view the stock details.